@article {OhPD6.006作者= {Jiwon哦Shiv Saidha和分钟陈赛斯史密斯和杰瑞和克雷格•琼斯和Peter Van Zijl王子和玛丽Diener-West和丹尼尔帝国和彼得·卡拉布雷西},title ={相对定量核磁共振测量的临床效用脊髓多发性硬化患者(PD6.006)},体积={80}={7}补充数量,页面= {PD6.006——PD6.006} ={2013},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:确定哪些脊髓MRI定量措施的组合(SC)是最能区分多发性硬化(MS)患者不同残疾水平。首页背景:SC病理学是常见的女士之前的研究已经表明,定量核磁共振在SC措施,包括发表和magnetization-transfer成像派生指标,和SC-cross-sectional区域(CSA),与医学相关临床残疾。相对这些MRI措施尚不清楚,临床实用程序和某些MRI措施可能更善于区分MS患者的残疾程度。设计/方法:124 MS患者接受颈3-tesla SC-MRI和被分类到子组基于扩展残疾状态量表(eds)评分和SC病灶计数。感兴趣的限制同样之间的SC截面轴向。SC-CSA,分数各向异性(FA),意味着扩散系数(MD),垂直/平行扩散系数(λA5; /λ| |),和magnetization-transfer比(地铁)计算。来确定哪个最好结合MRI措施将与残疾水平,多变量逻辑回归模型使用向前逐步选择(假定值截止= 0.10)是利用以残疾水平为因变量和MRI措施,年龄和性别作为潜在的协变量。结果:在所有患者中,女士的反是年龄、性别、SC-CSA, FA和地铁(p \ < 0.10)在模型中被保留。当患者分为低/高女士病灶计数,SC-CSA和地铁(p \ < 0.10)在低损伤保留不计数设置,只有年龄和FA (p \ < 0.10)保留在高损伤数设置。结论:结合SC-CSA、FA和地铁是最能区分MS患者的残疾程度,表明某些组合的MRI措施可能比其他人更预测临床效用。MRI的临床歧视性的能力组合措施不同设置的低/高病灶计数。前瞻性研究需要评估这些MRI措施在预测的预测效用残疾进展,这将扩大这些成像技术的临床应用。支持:加拿大社会的女士;国家社会女士。Disclosure: Dr. Oh has received research support from Teva Neuroscience and EMD Serono. Dr. Saidha has received personal compensation for activities with MedicalLogix and Teva Neurosciences. Dr. Chen has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Prince has received personal compensation for activities with Diagnosoft, Inc. Dr. Prince has received royalty payments from technology that Johns Hopkins owns and has licensed to Diagnosoft, Inc. Dr. Prince holds stock and/or stock options in Diagnosoft, Inc. Dr. Jones has received research support from Philips Medical Systems. Dr. Van Zijl has received personal compensation for activities with Philips Medical Systems and Kennedy Krieger Institute as speaker and/or consultant. Dr. Van Zijl has received research support from Philips Medical Systems. Dr. Diener-West has nothing to disclose. Dr. Reich has nothing to disclose. Dr. Calabresi has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Genzyme Corporation, Vaccinex, Vertex, and Novartis. Dr. Calabresi has received research support from the National Institutes of Health, the National Multiple Sclerosis Society, Nancy Davis Foundation, Biogen Idec, Vertex, Genentech, Inc., Abbott, and Bayer.Thursday, March 21 2013, 7:30 am-12:00 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/80/7_Supplement/PD6.006}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }